Seeking Alpha

fezziwig2008's  Instablog

Send Message
Research Background- I only invest in areas of interest that are familiar.
  • Amazing Growth In Herceptin SC Sales In Less Than 1 Year! HALO RHHBY 3 comments
    Jul 24, 2014 4:25 AM
    Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche


    SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc.(NASDAQ: HALO) today announced that the commercial launch of Herceptin® SC inEurope has triggered a $10 million milestone payment to Halozyme under the License and Collaboration Agreement between Halozyme and Roche. This time-saving subcutaneous formulation of Herceptin (trastuzumab) using Halozyme's recombinant human hyaluronidase (rHuPH20) received marketing authorization from the European Commission on August 28, 2013 for the treatment of patients with HER2-positive breast cancer and was launched upon approval. Herceptin SC reduces treatment times and enhances convenience compared to the standard intravenous (IV) form.


    "With pricing on par with the intravenous formulation, Herceptin SC represents a compelling treatment alternative for breast cancer patients in Europe, and we congratulate Roche on making this time-saving therapy available to patients inEurope so quickly," saidGregory I. Frost, Ph.D., President and Chief Executive Officer of Halozyme. "This will be the third commercial product using our rHuPH20 enzyme and represents a significant achievement for our technology and company as a whole."


    July 24, 2014 Roche 1/2 Year 2014 Presentation Slide 22

    Country Launch % Share of TOTAL Herceptin Sales

    Sweden Sept >50%

    Denmark Nov >50%

    UK Sept 50%

    Chile Dec 45%

    Finland Nov 40%

    Austria Sept 40%

    Norway Oct 40%

    Portugal Sept 18%

    Netherl Oct 15%

    Germany Sept 10%


    Roche will Use Herceptin SC as it's "Defense against Biosimilars", since all biosimilars are IV and require a 1-2 Hr infusion by skilled personnel vs a 5 min "jab" that family or the patient can be trained to administer at home. Look for Roche to advertise this distinction more as European patent expire on IV Herceptin in the coming year.

    The future of SC formulations of Herceptin and MabThera looks Bright for Halozyme.

    Disclosure: The author is long HALO.

Back To fezziwig2008's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (3)
Track new comments
  • mbw5014
    , contributor
    Comment (1) | Send Message
    Do we know any other of Roche's targets?
    24 Jul 2014, 09:13 AM Reply Like
  • fezziwig2008
    , contributor
    Comments (151) | Send Message
    Author’s reply » MabThera SC for Non Hodgkins Lymphoma- the #1 Roche Drug by Revenue- next possible competition for NHL- Gayzva- is not through trials until after 2017 at the earliest.
    24 Jul 2014, 09:13 PM Reply Like
  • fezziwig2008
    , contributor
    Comments (151) | Send Message
    Author’s reply » Here's an Interesting wrinkle from Reuters- Biosimilar maker Hosipra won a patent case in England against Roche that negates Roche's Herceptin IV patents as of 7/28/14- 3 days from this writing- So next week, the only patent protecting a Roche Herceptin product in the UK will be HALOZYME'S Enhanze patent! That makes HALO a bigger buyout target for Roche than ever before.


    24 Jul 2014, 10:58 PM Reply Like
Full index of posts »
Latest Followers


More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.